Bolt Biotherapeutics, Inc. (BOLT)

PriceLoading quote

Financial charts

Revenue

Net income

Free cash flow

Total cash / debt

CashTotal debt

Financial statements

6 annual periodsNewest to oldest
202520242023202220212020
Revenue$7.7M$7.7M$7.9M$5.7M$1.3M$231,000
Research & development$28.5M$57.5M$61.5M$73.1M$75.7M$40.4M
Operating expenses$43.8M$80.7M$84.1M$96.0M$94.0M$49.4M
Operating income−$36.1M−$73.0M−$76.2M−$90.3M−$92.8M−$49.2M
EBITDAderived−$34.8M−$71.3M−$74.3M−$88.7M−$91.6M−$48.6M
Net income−$33.4M−$63.1M−$69.2M−$88.1M−$98.6M−$60.7M
Basic EPSper diluted share-$17.85-$33.06-$1.83-$2.36-$2.97-$28.89
Diluted EPSper diluted share-$17.85-$33.06-$1.83-$2.36-$2.97-$28.89

Insider buys & sells

Jul 1, 2024Jun 30, 2026
Buys8$8.2K disclosed value
Sells (SEC code S)0$0.00 disclosed value
8 recent transactions
TransactionInsiderTypeSharesPriceValueOwned after
Dec 5, 2025Form 4Quinn William P.President, CEO and CFOBuyCommon Stock125$4.61$576.252.3K
Dec 5, 2025Form 4Nemec SarahSenior VP, Finance and PAOBuyCommon Stock125$4.61$576.251.4K
Jun 6, 2025Form 4Nemec SarahSenior VP, Finance and PAOBuyCommon Stock125$5.49$686.25943
Jun 6, 2025Form 4Quinn William P.President, CEO and CFOBuyCommon Stock125$5.49$686.252.2K
Dec 16, 2024Form 4Nemec SarahSenior VP, Finance and PAOBuyCommon Stock2.5K$0.50$1.3K16.6K